Allakos News Releases http://investor.allakos.com/ Allakos News Releases en Allakos Reports First Quarter 2019 Financial Results http://investor.allakos.com/news-releases/news-release-details/allakos-reports-first-quarter-2019-financial-results REDWOOD CITY, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the first quarter ended March 31, 2019. Wed, 08 May 2019 08:01:00 -0400 Allakos News Releases 6656 Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis http://investor.allakos.com/news-releases/news-release-details/allakos-announces-positive-results-ak002-patients-severe -- Substantial reduction of patient reported symptoms and physician assessed signs and symptoms -- -- Improvements also observed in atopic dermatitis, asthma and allergic rhinitis -- -- Conference call and webcast today at 5:00 pm ET -- REDWOOD CITY, Calif. Tue, 07 May 2019 16:01:00 -0400 Allakos News Releases 6641 Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights http://investor.allakos.com/news-releases/news-release-details/allakos-reports-fourth-quarter-and-full-year-2018-financial REDWOOD CITY, Calif. , March 14, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018, and provided Thu, 14 Mar 2019 16:01:00 -0400 Allakos News Releases 6601 Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis http://investor.allakos.com/news-releases/news-release-details/allakos-announces-positive-phase-1-results-ak002-indolent AK002 has now shown clinical activity in multiple mast cell diseases REDWOOD CITY, Calif. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive multiple dose Tue, 19 Feb 2019 08:00:00 -0500 Allakos News Releases 6571 Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts http://investor.allakos.com/news-releases/news-release-details/allakos-announces-positive-phase-2-results-ak002-patients-xolair -- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients -- -- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by HSS7 in Xolair Naïve CSU patients -- -- 54% (7/13) complete itch response by ISS7 in Xolair Naïve CSU patients -- -- 54% Mon, 11 Feb 2019 08:00:00 -0500 Allakos News Releases 6541 Allakos to Host Investor Day on February 19 in New York City http://investor.allakos.com/news-releases/news-release-details/allakos-host-investor-day-february-19-new-york-city REDWOOD CITY, Calif. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19 th starting at 12:00 pm ET in New York City Mon, 04 Feb 2019 08:00:00 -0500 Allakos News Releases 6531 Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism http://investor.allakos.com/news-releases/news-release-details/allakos-announces-positive-phase-2-results-patients-cholinergic -- 82% (9 of 11) response rate in patients with cholinergic urticaria -- -- 70% (7 of 10) response rate in patients with symptomatic dermographism -- REDWOOD CITY, Calif. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of Tue, 29 Jan 2019 08:00:00 -0500 Allakos News Releases 6521 Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients http://investor.allakos.com/news-releases/news-release-details/allakos-announces-positive-phase-2-results-cohort-xolair-naive -- 12 of 13 (92%) patients achieved a complete response -- -- Results from 3 additional cohorts expected in the first quarter of 2019 -- REDWOOD CITY, Calif. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and Mon, 07 Jan 2019 08:00:00 -0500 Allakos News Releases 6506 Allakos Announces Clinical Update and Third Quarter 2018 Financial Results http://investor.allakos.com/news-releases/news-release-details/allakos-announces-clinical-update-and-third-quarter-2018 -- Clinical data expected in early first quarter 2019 -- SAN CARLOS, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced Thu, 08 Nov 2018 16:01:00 -0500 Allakos News Releases 6486 Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting http://investor.allakos.com/news-releases/news-release-details/allakos-presents-data-its-eosinophilic-gastrointestinal-diseases SAN CARLOS, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced the presentation of two posters at the American College Mon, 08 Oct 2018 08:00:00 -0400 Allakos News Releases 6466